Bui A, et al. - Via performing a systematic review, researchers examined the efficiency of Pulmonary function tests (PFTs), including the diffusing capacity for carbon monoxide (DLCO), for early detection of drug-induced interstitial lung disease (DILD) in a range of drugs. Searching OvidMEDLINE and EMBASE from 1946 to February 2018, they identified 4,065 citations, and included 42 studies. Drugs that were most commonly studied were bleomycin and amiodarone. They noted variations in the sensitivity of monitoring with DLCO—from 0% to 100%; the majority of studies reported a sensitivity of < 80%. For most studies, wide CIs were reported. The specificity of < 90% was reported in all studies. These findings thereby do not advocate routine PFTs for early detection of DILD. Significant uncertainty about the sensitivity of PFTs to screen for DILD was evident because of methodological limitations, the relatively small number of participants, and the low prevalence of DILD in the included studies.